ALT
Altimmune, Inc.5.03
-0.25-4.73%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A confirms Phase III on track
Q&A largely reaffirmed prepared remarks on PEMB's Phase III readiness, with management confirming FDA-aligned design powered over 90% for NASH resolution and fibrosis endpoints, no changes from new single-trial framework or EU advice. They detailed final tweaks like 2+1 AI-assisted pathologist reads and plans to enroll semaglutide dropouts while probing muscle preservation via MRI/DEXA sub-study. Competitive edge stressed on tolerability and balanced agonism versus Servier, BI. Financing queries met with confidence in $340M cash to 2028. Execution mode engaged. Tone stayed bullish; watch AUD Q3 data, trial kickoff.
Key Stats
Market Cap
524.84MP/E (TTM)
-Basic EPS (TTM)
-1.07Dividend Yield
0%Recent Filings
10-K
FY2025 results
Altimmune's FY2025 10-K lacks financial statements, revealing no revenue or profitability figures for the year ended December 31, 2025, or Q4 contribution. Pemvidutide drove key milestones, with IMPACT Phase 2b topline results on June 26, 2025, showing 58.2% MASH resolution at 1.2mg and 52.1% at 1.8mg versus 19.9% placebo in ITT analysis at 24 weeks. No quarterly breakdowns disclosed. Cash position undisclosed. No guidance provided. Clinical trial delays threaten momentum.
8-K
Q4 results, $274M cash
Altimmune reported Q4 and full-year 2025 results, with cash at $274 million up 107% from 2024, bolstered by $75 million raised in January 2026. Pemvidutide earned FDA Breakthrough Therapy Designation in MASH; Phase 3 trial starts 2026, RECLAIM Phase 2 topline due Q3. Losses narrowed to $88.1 million yearly. Cash fuels pipeline push.
8-K
2026 AGM set April 16
Altimmune set its 2026 Annual Meeting for April 16, 2026, shifting from last year's September 25 date to match standard Q2 timing for December fiscal year-ends. Record date is March 13; stockholder proposals and nominations due by February 13, 2026. Deadlines tightened due to the >30-day change. Virtual format expected.
8-K
Altimmune raises $75M
Altimmune inked a securities purchase agreement on January 27, 2026, for a registered direct offering of 12.4M common shares and pre-funded warrants for 4.6M more to a new institutional investor, expecting ~$75M gross proceeds before fees, closing around January 29. Directors and execs locked up sales for 30 days post-close. Cash bolsters runway.
8-K
Pemvidutide hits fibrosis marks
Altimmune announced positive 48-week topline data from the IMPACT Phase 2b trial of pemvidutide in MASH patients on December 19, 2025. Doses of 1.2 mg and 1.8 mg drove statistically significant reductions in ELF (-0.49 and -0.58 vs. +0.16 placebo) and LSM, plus 45.2% and 54.7% liver fat drops, with 7.5% weight loss at 1.8 mg. Tolerability stayed strong, discontinuations below placebo. FDA End-of-Phase 2 meeting backs Phase 3 push.
AIM
AIM ImmunoTech Inc.
1.38+0.06
ETNB
89bio, Inc.
14.84+0.00
IMA
ImageneBio, Inc.
6.25+0.08
IMRX
Immuneering Corporation
5.74-0.04
IMVT
Immunovant, Inc.
26.61+0.61
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
MTSR
Metsera, Inc.
70.50-0.25
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SGMT
Sagimet Biosciences Inc. - Seri
6.05+0.02
TCRT
Alaunos Therapeutics, Inc.
4.36+0.09